Key Takeaway
After 6 months on GLP-1 medications, most patients lose 15 to 40 pounds depending on the medication. Here is a comparative breakdown with clinical data.
Six months is a landmark moment for anyone on GLP-1 therapy. If you're researching GLP-1 results after 6 months, the picture is encouraging across all medications in the class: most patients have lost 15 to 40 pounds depending on which medication they take, with substantial improvements in blood sugar, blood pressure, cholesterol, and overall quality of life .
Six-Month Comparison Across GLP-1 Medications
| Medication | Typical 6-Month Weight Loss | Body Weight % Lost | Dose at 6 Months |
|---|---|---|---|
| Semaglutide (Wegovy 2.4 mg) | 20 to 35 lbs | 9% to 14% | 2.4 mg maintenance |
| Semaglutide (Ozempic) | 15 to 25 lbs | 7% to 10% | 1.0 to 2.0 mg |
| Tirzepatide (Zepbound/Mounjaro) | 25 to 45 lbs | 11% to 18% | 10 to 15 mg |
| Liraglutide (Saxenda) | 12 to 20 lbs | 5% to 9% | 3.0 mg (max) |
| Compounded semaglutide | 18 to 32 lbs | 8% to 13% | 1.7 to 2.4 mg |
Tirzepatide clearly leads at the six-month mark, followed by high-dose semaglutide (Wegovy). Liraglutide produces more modest results, which is why it has been largely superseded by newer agents .
Health Improvements Across the GLP-1 Class at 6 Months
Regardless of which medication you take, six months of GLP-1 therapy typically produces improvements across multiple health domains :
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
| Health Marker | Typical Improvement |
|---|---|
| Systolic blood pressure | 8 to 15 mmHg decrease |
| A1C (diabetic patients) | 1% to 3% decrease |
| Triglycerides | 15% to 35% decrease |
| LDL cholesterol | 5% to 15% decrease |
| Liver enzymes (ALT) | 20% to 40% decrease |
| CRP (inflammation marker) | 25% to 50% decrease |
These improvements collectively reduce your risk of heart attack, stroke, kidney disease, and other obesity-related conditions. The SELECT trial[1] demonstrated that semaglutide reduced cardiovascular events by 20% in overweight patients with established cardiovascular disease .
What Daily Life Looks Like at 6 Months
By the six-month mark, your medication routine is second nature and your new eating patterns feel normal:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Meals: Three moderate, protein-focused meals with minimal snacking. Portions that once seemed small now feel perfectly adequate.
- Exercise: Most patients have an established routine. Activities that were difficult at your higher weight are now manageable or even enjoyable.
- Energy: Consistently higher than before treatment. Fewer crashes, better endurance, improved recovery.
- Clothing: 2 to 5 sizes smaller depending on total weight lost. Many patients have rebuilt their wardrobe by this point.
- Social interactions: People notice and comment on the change. This can be positive but also requires emotional adjustment.
Common Concerns at Six Months
- Weight loss slowing: The rate of loss often begins to decelerate around months 5 to 7. This is normal and doesn't mean the medication stopped working.
- Muscle preservation: If you haven't been strength training, now is the time to start. Lean mass loss is a real risk with significant weight reduction .
- Hair changes: Telogen effluvium peaks around this time. It's temporary and resolves as weight stabilizes.
- Cost sustainability: Six months of medication costs add up. Discuss compounded options if affordability is a concern FormBlends pricing.
- Treatment duration questions: Should you continue? For how long? Your provider will help assess based on your progress and goals.
Strategies for the Next Six Months
- thorough blood work. Full metabolic panel, lipids, CBC, thyroid, vitamin D, and B12.
- Body composition scan. Measure fat-to-muscle ratio to ensure you're losing the right kind of weight.
- Progressive overload in training. Gradually increase weights and intensity in your exercise routine.
- Discuss dose improvement. You may be able to maintain results at a lower dose, reducing cost and side effects.
- Plan for long-term maintenance. Whether you continue medication or plan to taper, having a strategy prevents rebound weight gain FormBlends telehealth consultation.
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
Which GLP-1 has the best results at 6 months?
Tirzepatide (Zepbound/Mounjaro) produces the most weight loss at six months, followed by high-dose semaglutide (Wegovy). The best choice depends on your individual response, health needs, and budget GLP-1 medication comparison.
Is it safe to continue GLP-1 medications beyond 6 months?
Yes. All major GLP-1 medications have been studied for 52 to 72 weeks, and long-term safety data is reassuring. Many patients continue for a year or longer .
What if my weight loss has plateaued at 6 months?
Plateaus are common and temporary. Strategies include adjusting your calorie intake, increasing exercise intensity, improving sleep quality, and potentially adjusting your dose. Your provider can help identify the best approach.
Can I switch GLP-1 medications at 6 months?
Yes. Switching from semaglutide to tirzepatide (or vice versa) is possible and sometimes produces additional weight loss. Your provider will determine the appropriate starting dose on the new medication .
How do I maintain my weight loss long term?
Long-term maintenance typically involves continued medication (possibly at a lower dose), regular exercise, protein-focused nutrition, and ongoing provider support. Research shows that discontinuing GLP-1 medications leads to weight regain in most patients .